These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2129015)

  • 1. Antibody-directed fibrinolysis: a bispecific (Fab')2 that binds to fibrin and tissue plasminogen activator.
    Runge MS; Bode C; Savard CE; Matsueda GR; Haber E
    Bioconjug Chem; 1990; 1(4):274-7. PubMed ID: 2129015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
    Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
    J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
    Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
    Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate.
    Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
    J Mol Cell Cardiol; 1987 Apr; 19(4):335-41. PubMed ID: 3612817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
    Runge MS; Bode C; Matsueda GR; Haber E
    Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
    Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
    Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.
    Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
    J Biol Chem; 1987 Aug; 262(22):10819-23. PubMed ID: 3611093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
    Kurokawa T; Iwasa S; Kakinuma A
    Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid molecules: insights into plasminogen activator function.
    Runge MS; Bode C; Haber E; Quertermous T
    Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugation and evaluation of 7E3 x P4B6, a chemically cross-linked bispecific F(ab')2 antibody which inhibits platelet aggregation and localizes tissue plasminogen activator to the platelet surface.
    Neblock DS; Chang CH; Mascelli MA; Fleek M; Stumpo L; Cullen MM; Daddona PE
    Bioconjug Chem; 1992; 3(2):126-31. PubMed ID: 1515466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue-type plasminogen activator.
    Wojta J; Beckmann R; Turcu L; Wagner OF; van Zonneveld AJ; Binder BR
    J Biol Chem; 1989 May; 264(14):7957-61. PubMed ID: 2470738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
    Bos R; Nieuwenhuizen W
    Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
    Runge MS; Bode C; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase.
    Charpie JR; Runge MS; Matsueda GR; Haber E
    Biochemistry; 1990 Jul; 29(27):6374-8. PubMed ID: 1698452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.
    Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C
    Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remaining perspectives of mutant and chimeric plasminogen activators.
    Lijnen HR; Collen D
    Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PC-12 cells hydrolyze the fibrin clot by producing both plasminogen and its tissue activator].
    Petrova IuI; Savchuk OM; Kalashnyk OM; Platonova TM; Skok MV; Cederholm-Williams S
    Ukr Biokhim Zh (1999); 2004; 76(2):64-8. PubMed ID: 15915713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.
    Bu C; Gao L; Xie W; Zhang J; He Y; Cai G; McCrae KR
    Arthritis Rheum; 2009 Feb; 60(2):559-68. PubMed ID: 19180513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.